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ABSTRACT: Background. There is an ongoing debate about the value of
(neo-)adjuvant chemotherapy in high- and intermediate-grade osteosar-
coma of the head and neck.
Methods. All records of patients older than 16 years diagnosed with
osteosarcoma of the head and neck in the Netherlands between 1993
and 2013 were reviewed.
Results. We identified a total of 77 patients with an osteosarcoma of the
head and neck; the 5-year overall survival (OS) was 55%. In 50 patients
with surgically resected high- or intermediate-grade osteosarcoma of
the head and neck younger than 75 years, univariate and multivariable
analysis, adjusting for age and resection margins, showed that patients
who had not received chemotherapy had a significantly higher risk of
local recurrence (hazard ratio [HR]5 3.78 and 3.66, respectively).
Conclusion. In patients younger than 75 years of age with surgically
resected high- and intermediate-grade osteosarcoma of the head and neck,
treatment with (neo-)adjuvant chemotherapy resulted in a significantly
smaller risk of local recurrence. Therefore, we suggest (neo-)adjuvant che-
motherapy in patients amenable to chemotherapy. VC 2016 The Authors
Head & Neck Published by Wiley Periodicals, Inc. Head Neck 39: 140–146,
2017
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INTRODUCTION
Osteosarcoma is an aggressive bone tumor characterized by
the formation of osteoid by malignant osteoblasts.1 It most
commonly occurs in the extremities and mainly effects
teenagers and young adults. Osteosarcoma of the head and
neck accounts for approximately 6% of all osteosarcomas.2
The current treatment for extremity osteosarcomas is neo-
adjuvant chemotherapy followed by surgery and adjuvant
chemotherapy. One of the main aims of chemotherapy
is early treatment of occult distant metastases. Since the
introduction of chemotherapy, the overall survival (OS)
improved dramatically with a 5-year OS of about 60% to
70% currently.3 Osteosarcoma of the head and neck
behaves differently from extremity osteosarcoma. First, the
median age is at least 2 decades higher.4 Second, although
patients with extremity osteosarcoma have a very high risk
of metastatic disease of the lungs (44% to 49%),5 pulmo-
nary metastases are less common in patients with osteosar-
coma of the head and neck (4% to 43%).6,7 Furthermore,
local recurrences predominate in osteosarcoma of the head
and neck with a reported incidence of 17% to 70%2,8 com-
pared with 5% to 7% in extremity osteosarcoma.5 This
could be attributed to the difficulty to obtain tumor-free
margins by surgery in the head and neck region.
In view of these differences, there is an ongoing debate
about the value of (neo-)adjuvant chemotherapy in the treat-
ment for osteosarcoma of the head and neck. The opponents
of chemotherapy argue that, because pulmonary metastases
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only occasionally develop, chemotherapy has no role in the
primary treatment of osteosarcoma of the head and neck.
Because of the rarity of the disease, only small retrospective
case series have been described.7,9,10 The single meta-
analysis (173 patients) and systematic review (201 patients)
show conflicting results about the use of (neo-)adjuvant
chemotherapy.4,11
The purpose of this retrospective study — with a
review of each individual medical report — was to
describe the treatment and outcomes of patients who were
diagnosed with osteosarcoma of the head and neck in The
Netherlands over the last 2 decades, with special attention
to the role of (neo-)adjuvant chemotherapy.
PATIENTS AND METHODS
A retrospective cohort study was conducted in patients
diagnosed with osteosarcoma of the head and neck from
1993 until July 2013 within the Dutch Head and Neck
Society.
Local pathologists of the 8 participating head and neck
centers were asked to provide a search with the term
‘osteosarcoma” in combination with head and neck
locations, such as “jaw,” “mandible,” “maxilla,” “larynx,”
or “skull.” Patients older than 16 years of age with a histo-
pathological proven diagnosis of osteosarcoma and with a
primary location in the head and neck region were included.
In the Netherlands, there is a special multidisciplinary
expert team available for reviewing cases with bone tumors
(Netherlands Committee on Bone Tumors [NCBT]). For all
patients in this study, histological evaluation was (also) per-
formed and confirmed by either the NCBT or an experi-
enced pathologist’s part of the NCBT in their affiliated
hospitals. For all cases in which histological grade was
either intermediate or not reported, hematoxylin-eosin
stained slides were retrieved from the archives and revised
by 2 experienced musculoskeletal pathologists (J.B. and
U.F.).
All medical records were reviewed for patients’ charac-
teristics, such as age, sex, and medical history, as well as
information concerning diagnosis (location, grading, and
subtype), treatment (surgery, radiotherapy, and chemo-
therapy), occurrence of local recurrence or distant metas-
tases, and survival.
Data analysis
Resection margins were classified by pathological assess-
ment and categorized in 3 categories; intralesional, marginal,
or wide, according to Enneking et al.12 Intralesional and
unknown resection margins were considered incomplete,
whereas marginal and wide resection margins were consid-
ered complete. OS was defined as time (in months) from date
of diagnosis until date of death of any cause; patients alive at
last known follow-up date were censored. Disease-free sur-
vival (DFS) was defined as time (in months) from surgery
until the date of the first event (local recurrence, distant
metastases, or death), patients alive without disease at last
known follow-up date were censored. Local recurrence and
distant metastases were measured by radiological evaluation
and preferably confirmed by pathological assessment.
Patients without surgical resection were not included in the
DFS calculations or survival figures. Local recurrence-free
interval (LRFI) was defined as time (in months) from surgery
until the occurrence of a local recurrence. Patients without a
local recurrence were censored at the date of death or last
known follow-up date.
Statistical analysis
The Kaplan–Meier method was performed to create sur-
vival figures. Log-rank tests were used to compare the
survival curves between groups. The adjustment of the
HR for chemotherapy for confounders was restricted to
age and resection margins in a Cox regression model
because of the limited number of events. The analysis of
the effect of chemotherapy on OS, DFS, and LFRI was
limited to surgical-resected patients with high or interme-
diate grade osteosarcoma of the head and neck and <75
years of age, because (neo-)adjuvant chemotherapy for
elderly patients is not considered in this setting. The size
of the effect of chemotherapy was defined as the ratio
between the hazard of the event in the patients who were
not treated with chemotherapy and the hazard of the event
in the patients treated with chemotherapy. It was calculat-
ed using a Cox proportional hazards regression model.
HRs are reported with 95% confidence interval (95% CI).
A p value of < .05 was considered to be significant. The
data were analyzed using SPSS version 20.
RESULTS
Patients’ characteristics and treatment of the 77
patients with osteosarcoma of the head and neck
A total of 77 patients with osteosarcoma of the head and
neck were identified. Thirty-six patients (47%) were men
and the median age at diagnosis was 46 years (range, 16–95
years). Patients’ characteristics are summarized in Table 1. A
total of 25 patients (33%) had a previous malignancy.
The median age at the time of diagnosis of this first non-
osteosarcoma of the head and neck primary tumor was
30 years (range, 1–77 years). Seven patients had multiple pri-
mary malignancies. One case of Li-Fraumeni syndrome was
identified. Four patients were treated for retinoblastoma in
childhood. Twenty-two patients (29%) previously received
radiotherapy, of which 19 (86%) were in the head and neck
region. The median age at the time of the previous radiother-
apy of the head and neck was 30 years (range, 1–77 years).
The median time between the prior radiotherapy and the
presentation of the osteosarcoma of the head and neck was
16 years (range, 7–60 years). The most common tumor loca-
tion was the jaw (73%; Table 1). Fifty-eight tumors (75%)
were classified as high-grade, 6 (8%) as intermediate-grade,
and 11 (14%) as low-grade osteosarcoma. At the time of
diagnosis, none of the patients had involvement of the lymph
nodes in the neck and only 1 patient presented with pulmo-
nary metastases.
Patients were treated according to the local policy of the
multidisciplinary head and neck cancer working group. Sev-
enty patients (91%) underwent surgical resection. In total, 17
patients (22%) received radiotherapy. The median dose was
58 Gy (range, 8–70 Gy). Fourteen patients received postoper-
ative radiotherapy because of irradical resection, 2 other
patients received radiotherapy as single treatment, and 1
patient received radiotherapy because of tumor bleeding.
The 5-year OS was 55% for all 77 patients.
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Low grade osteosarcoma of the head and neck
All patients with low-grade osteosarcoma of the head
and neck (n 5 11) underwent surgical resection. Only 1
patient (9%) received postoperative radiotherapy because
of an intralesional resection. None of them were treated
with chemotherapy. After a median follow-up time of 106
months (range, 15–198 months), none of the patients
developed a local recurrence or distant metastases. One
patient had a second primary malignancy. One patient
died without evidence of disease. The 5-year OS and
DFS were both 90% (Figure 1A and 1B).
High- or intermediate-grade osteosarcoma
of the head and neck
Sixty-four patients had high- or intermediate-grade osteo-
sarcoma of the head and neck. Fourteen patients were
excluded from further analysis for the effect of chemothera-
py because of their age (75 years or older) or because no
surgical resection was performed. The characteristics of the
remaining 50 patients are displayed in Table 1 according to
treatment with (neo-)adjuvant chemotherapy. Treatment
characteristics are shown in Figure 2.
Treatment
A total of 29 patients (58%) received chemotherapy, of
whom 12 patients (41%) received neoadjuvant, 8 (28%)
received adjuvant, and 9 (31%) received both neoadjuvant
and adjuvant chemotherapy. The most frequently used
chemotherapy consisted of a combination of cisplatin and
doxorubicin. The median number of cycles of chemother-
apy was 4 (range, 1–6 cycles).
After neoadjuvant chemotherapy (n 5 21), the resection
specimens showed >90% tumor necrosis in 5 patients
(24%). Forty-five percent of chemotherapy-treated patients
had a complete resection versus 48% in patients who did
not receive chemotherapy (Table 1). Six patients (21%)
treated with chemotherapy and 5 patients (24%) not treated
with chemotherapy received radiotherapy (Figure 2).
TABLE 1. Patients’ and tumor characteristics for all patients (n5 77) and for patients with high- and intermediate-grade resected osteosarcoma of the
head and neck, age <75 years according to treatment with (neo-)adjuvant chemotherapy.
High- and intermediate-grade resected osteosarcoma
of the head and neck, age <75 y
All patients
No. of patients 5 77
No. of patients (%)
Chemotherapy
No. of patients 5 29
No. of patients (%)
No chemotherapy
No. of patients 5 21
No. of patients (%)
Sex
Male 36 (47) 16 (55) 10 (48)
Female 41 (53) 13 (45) 11 (52)
Age, y
Median (range) 46 (16–95) 41 (16–74) 57 (19–75)
Tumor site
Maxilla 24 (31) 8 (28) 5 (24)
Mandible 32 (42) 11 (38) 11 (52)
Paranasal sinuses 7 (9) 4 (14) 0
Skull bone 4 (5) 2 (7) 2 (10)
Skull base 2 (3) 0 1 (5)
Orbital bone 3 (4) 3 (10) 0
Ethmoid bone 2 (3) 0 0
Other 3 (4) 1 (3) 2 (10)
Osteosarcoma subtype
Conventional 51 (66) 13 (45) 11 (52)
Chondroblastic 11 (14) 7 (24) 6 (29)
Osteoblastic 6 (8) 6 (21) 2 (10)
Sclerosing 2 (3) 2 (7) 0
Fibroblastic 7 (9) 1 (3) 2 (10)
Grade
Low 11 (14) 0 0
Intermediate 6 (8) 3 (10) 3 (14)
High 58 (75) 26 (90) 18 (86)
Unknown 2 (3) 0 0
Resection margins
Complete, no. (%) 38 (49) 13 (45) 10 (48)
Incomplete, no. (%) 32 (42) 16 (55) 11 (52)
No surgery, no. (%) 7 (9)
Median follow-up time in mo (range) 34 (0–223) 30 (4–181) 44 (1–223)
Local recurrence 14 2 8
Local recurrence and distant metastases 7 1 5
Distant metastases 4 2 1
Deaths 35 8 13
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Recurrent disease and survival
The numbers of local recurrences and/or distant metasta-
ses in patients with a high- or intermediate-grade osteosar-
coma of the head and neck and aged <75 years are shown
in Table 1. After a median follow-up time of 30 months
(range, 4–181 months) and 44 (range, 1–223 months),
respectively, 8 patients in the chemotherapy treated and 13
patients in the non-chemotherapy treated group had died.
The 5-year OS was 66% versus 51% in the chemotherapy
versus non-chemotherapy treated patients, respectively, and
the respective 5-year DFS was 67% versus 33%.
Prognostic factors
Univariate analysis. In univariate analyses, surgical resected
patients with a high- or intermediate-grade osteosarcoma of
the head and neck, aged <75 years, and not treated with (neo-
)adjuvant chemotherapy had a significantly worse DFS (HR
5 2.50; 95% CI 5 1.09–5.71; p 5 .030) and higher risk of
local recurrence (HR 5 3.78; 95% CI 5 1.35–10.62; p 5
.012). There was no significant difference in OS (HR 5 1.60;
95% CI 5 0.66–3.86; p 5 .30). Patients with an incomplete
resection had a significantly worse OS (HR 5 2.75; 95% CI
5 1.13–6.73; p 5 .026), DFS (HR 5 2.56; 95% CI 5 1.10–
5.93; p 5 .029), and higher risk of local recurrence (HR 5
3.66; 95% CI5 1.29–10.38; p5 .015). Male sex, radiothera-
py, and age were not significant prognostic factors in a univar-
iate analysis for OS, DFS, and LRFI (Table 2).
Multivariable analysis. In a multivariable analysis, surgical
resected patients with a high- or intermediate-grade
osteosarcoma of the head and neck, aged <75 years, and
not treated with (neo-)adjuvant chemotherapy had a sig-
nificantly higher risk of a local recurrence when adjusted
for age and resection margins (HR 5 3.66; 95% CI 5
1.21–11.08; p 5 .022). Chemotherapy had no significant
impact on OS and DFS.
Patients with an incomplete surgical resection had a sig-
nificant worse OS (HR 5 3.72; 95% CI 5 1.43–9.69; p 5
.007), DFS (HR 5 3.10; 95% CI 5 1.28–7.55; p 5 .013),
and higher risk of local recurrence (HR 5 3.72; 95% CI 5
1.28–10.79; p5 .016) when adjusted for age and chemother-
apy (Table 2).
In a univariate analysis, there was an indication for age as
a prognostic factor for OS (p 5 .072). In a multivariable
analysis, age actually was a significant prognostic factor for
OS (HR 5 1.03; 95% CI 5 1.00–1.06; p 5 .03), but not for
DFS and LRFI (Table 2).
OS, DFS, and LRFI for patients according to both che-
motherapy and resection margins are shown in Figure 3A
to 3C. Figure 3C gives the probability of local recurrence
in the absence of the competing risk of death.
DISCUSSION
Because of the rarity of OSHN, conflicting results of in
general small case series, and the lack of clinical studies,
the role of chemotherapy in the treatment of patients with
OSHN is a continuous subject for debate. We performed
one of the largest case studies so far, including data of
treatment of all individual patients and showed that
patients aged <75 years with high or intermediate-grade
resected osteosarcoma of the head and neck and treated
with (neo-)adjuvant chemotherapy had a significant
smaller risk on local recurrence in univariate and multi-
variable analyses when adjusting for age and resection
margins. Although this effect was not shown for OS and
DFS in a multivariable analysis, this observation has
important implications. A local recurrence in the head
and neck region, in general, causes serious problems with
hardly any curative options. Often, this palliative phase is
dominated by (neuropathic) pain, speech impairment, and
swallowing dysfunction with a strongly negative impact
on the quality of life. Accordingly, prolonged LRFI is
considered beneficial for the patient. We showed that this
could be achieved by administration of (neo-)adjuvant
chemotherapy and, although we cannot present toxicity
data of the chemotherapy given, our results suggest that
the use of (neo-)adjuvant chemotherapy is an advantage
for patients aged younger than 75 years with high- or
intermediate-grade surgically resected osteosarcoma of
the head and neck.
FIGURE 1. (A) Overall survival estimation stratified by the differen-
tiation grade of the tumor of all patients (log-rank p 5 .023). Two
patients were left out of this figure because of an unknown dif-
ferentiation grade. (B) Disease-free survival estimation stratified
by the differentiation grade of the tumor of resected patients
(log-rank p 5 .029). Nine patients were left out of this figure; 2
patients because of an unknown differentiation grade, and 7
patients for not having surgery, and, thus, not being disease-free
at any time.
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Patients with intermediate-grade osteosarcoma of the
head and neck were analyzed together with high-grade
patients, because the natural course of disease is more in
accordance with high-grade than with low-grade osteosar-
coma of the head and neck. This is shown by our own data
and by a French cohort of patients with mandibular osteo-
sarcoma.13 Patients with low-grade disease were excluded
because of the less aggressive natural course of disease.
Based on expected toxicity, chemotherapy is not considered
for patients above a certain age. Therefore, only patients
younger than 75 years with surgical resections were includ-
ed for univariate and multivariable analysis.
As far as we know, this is the first report of an effect of
chemotherapy on LRFI in osteosarcoma of the head and
neck. A systematic review of 201 patients reported an OS
and DFS benefit for chemotherapy-treated patients in those
with a complete as well an incomplete resection.4 An effect
of chemotherapy on LRFI was not reported in this study.
A recently published large French cohort of 111 patients
with mandibular osteosarcomas, in both children and adults,
FIGURE 2. Treatment algorithm for all patients with special notice to patients with high- or intermediate-grade resected osteosarcoma of the head
and neck, aged <75 years.
TABLE 2. Univariate and multivariable analysis for high- and intermediate-grade resected osteosarcoma of the head and neck, aged <75 years, for overall
survival, disease-free survival, and local recurrence-free interval.
High-1 intermediate-grade,
resected patients, age <75 y
OS
HR (95% CI) p value
DFS
HR (95% CI) p value
LRFI
HR (95% CI) p value
Univariate analysis (No. of patients 5 50)
Age, y 1.02 (1.00–1.05) .072 1.02 (0.99–1.04) .16 1.01 (0.98–1.04) .49
Incomplete resection 2.75 (1.13–6.73) .026 2.56 (1.10–5.93) .029 3.66 (1.29–10.38) .015
No chemotherapy 1.60 (0.66–3.86) .30 2.50 (1.09–5.71) .030 3.78 (1.35–10.62) .012
Male sex 0.83 (0.34–2.00) .67 0.88 (0.39–1.99) .76 1.27 (0.50–3.24) .62
Radiotherapy 1.76 (0.64–4.89) .28 1.70 (0.66–4.36) .27 1.68 (0.59–4.74) .33
Multivariable analysis (No. of patients 5 50)
Age, y 1.03 (1.00–1.06) .03 1.02 (0.99–1.04) .23 1.00 (0.97–1.03) .87
Incomplete resection 3.72 (1.43–9.69) .007 3.10 (1.28–7.55) .013 3.72 (1.28–10.79) .016
No chemotherapy 1.06 (0.40–2.77) .91 2.10 (0.85–5.18) .11 3.66 (1.21–11.08) .022
Abbreviations: OS, overall survival; HR, hazard ratio; 95% CI, 95% confidence interval; DFS, disease-free survival; LRFI, local recurrence-free interval.
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showed improved DFS (HR 5 2.87; 95% CI 5 1.10–7.51;
p5 .025) and metastatic-free survival (HR5 4.40; 95% CI
5 1.46–13.28; p 5 .004) by (neo-)adjuvant chemotherapy,
but no effect on OS.13 These results are in line with our
findings of an HR of 2.50 (95% CI 5 1.09–5.71; p 5 .030)
of chemotherapy on DFS in a univariate analysis, and no
effect on OS. A meta-analysis of 173 patients did not find a
survival benefit for adjuvant chemotherapy; however,
resection margins were not taken into account.11 The
Surveillance, Epidemiology, and End Results database for
541 patients with osteosarcoma of the jaw did not provide
data on chemotherapy.14
Patients with low-grade osteosarcoma of the head and
neck have a less aggressive natural course of disease.
This was also observed in our group in which none of the
patients developed local recurrences or distant metastases
and long-term OS and DFS were both 90%. Therefore,
these findings do not support the use of (neo-)adjuvant
chemotherapy in patients with low-grade osteosarcoma of
the head and neck.
A history of cancer and/or irradiation is a well-
recognized risk factor for development of osteosarcoma of
the head and neck.13 We report a high incidence of
previous malignancy (33%). Whether this is due to germ
line susceptibility and/or external factors remains to be
explored. We had a high percentage of patients (25%) pre-
viously irradiated in the head and neck region, which was
even more frequent than the reported 15% for mandibular
osteosarcomas.13
One of the limitations of this study was its retrospective
design. Although care for osteosarcoma of the head and
neck is centralized in the 8 centers of the Dutch Head
and Neck Society, heterogeneity exists between the cen-
ters. However, a multidisciplinary approach is always
used in all centers. Because of the small number of
patients, only a limited number of events occurred and,
thus, only a limited number of prognostic factors could
be included in the multivariable analysis. The presence of
comorbidity was not taken into account.
One of the strong points of this series was the individ-
ual base of data collection, studying all patients’ medical
records. Histological classification was confirmed by
either the NCBT or pathologists from the NCBT in their
affiliated hospitals. Furthermore, we have a long median
follow-up time, which leads to meaningful clinical
observations.
FIGURE 3. (A) Overall survival estimation for high-
and intermediate-grade resected osteosarcoma of
the head and neck aged <75 years according to
both resection margins and (neo-)adjuvant chemo-
therapy (log-rank p 5 .036). (B) Disease-free sur-
vival estimation for high- and intermediate-grade
resected osteosarcoma of the head and neck aged
<75 years according to both resection margins
and (neo-)adjuvant chemotherapy (log-rank p 5
.003). (C) Local recurrence-free interval estimation
for high- and intermediate-grade resected
osteosarcoma of the head and neck aged <75
years according to both resection margins and
(neo-)adjuvant chemotherapy (log-rank p5 .003).
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CONCLUSION
Patients with high- and intermediate-grade surgical
resected osteosarcoma of the head and neck aged younger
than 75 years treated with (neo-)adjuvant chemotherapy had
significantly smaller risk on local recurrence in both univari-
ate and multivariable analyses. Despite the limitations of this
study, we suggest the use of (neo-)adjuvant chemotherapy in
high- or intermediate-grade tumors in patients younger than
75 years, irrespective of resection margins, because of the
large impact on quality of life in case of a local recurrence.
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